Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas
Open Access
- 1 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 6 (1) , vdae029
Abstract
Diffuse intrinsic pontine gliomas (DIPGs) pose a significant challenge as a highly aggressive and currently incurable form of pediatric brain cancer, necessitating the development of novel therapeutic strategies. Omacetaxine, an FDA-approved protein synthesis inhibitor for treating certain hematological malignancies, was investigated for its potential antitumor effects against preclinical DIPG models. We employed primary DIPG cultures to study omacetaxine’s cytotoxicity and its impact on colony formation. Annexin V staining and flow cytometry assessed apoptosis. Wound healing assays evaluated migration, while western blotting determined inhibition of oncogenic proteins. We tested omacetaxine’s therapeutic efficacy in an orthotopic DIPG model and assessed brain penetration using mass spectrometry. We found a pronounced cytotoxic activity of omacetaxine against DIPG neurospheres, with low IC50 values of approximately 20 nM. Omacetaxine exerted its anti-proliferative effect by inhibiting protein synthesis and the induction of apoptotic pathways, evidenced by significant elevated levels of cleaved caspase 3 and cleaved PARP, both key markers of apoptosis. Omacetaxine effectively targeted oncogenic players such as PDGFRα and PI3K without additional effects on the mTOR signaling pathway. Furthermore, our study revealed the inhibitory effects of omacetaxine on cell migration, and a significant reduction in integrin/FAK signaling, which plays a crucial role in tumor progression and metastasis. Despite these promising in vitro effects, omacetaxine’s efficacy in an orthotopic DIPG model was limited due to inadequate penetration across the blood-brain barrier. As such, further research and advancements are crucial to improve the drug’s brain penetration, thus enhancing its overall therapeutic potential.Keywords
Funding Information
- Tour de Cure Matching Grant
- National Health and Medical Research Council (#2019056, APP2017898)
- Cancer Institute New South Wales Program (TPG2037)
This publication has 40 references indexed in Scilit:
- Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine gliomaPediatric Blood & Cancer, 2011
- Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine GliomaJournal of Clinical Oncology, 2011
- Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in miceLeukemia, 2009
- Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1Neuro-Oncology, 2007
- Chemotherapy for brain stem gliomasChild's Nervous System, 1999
- Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumorsJournal of Neuro-Oncology, 1990
- Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formationFEBS Letters, 1989
- Pharmacokinetics of homoharringtonine in dogsCancer Chemotherapy and Pharmacology, 1988
- Central nervous system (CNS) penetration of homoharringtonine (HHT)Journal of Neuro-Oncology, 1987
- Inhibition of Translation in Eukaryotic Systems by HarringtonineEuropean Journal of Biochemistry, 1977